# A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B

Source: https://onco.cc/trials/nct06499285/  
OnCo record `nct06499285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Elritercept run by Takeda, now recruiting.

## Summary

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions is a phase 3 interventional study registered as NCT06499285 by Takeda, with 225 participants planned, started 2025-05-06. Conditions listed: Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06499285
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
- Sponsor: Takeda
- Enrolled: 225

## Sources

- ClinicalTrials.gov NCT06499285: https://clinicaltrials.gov/study/NCT06499285

## Connected records

- drugs: [Elritercept](https://onco.cc/drugs/elritercept/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct06499285.json